Aldeyra Therapeutics (ALDX) Total Liabilities (2013 - 2026)
Aldeyra Therapeutics' (ALDX) quarterly Total Liabilities came in at $24.3 million in Q1 2026, down 17.81% YoY from $29.6 million in Q1 2025, and down 12.52% on a QoQ basis from $27.8 million in Q4 2025.
Aldeyra Therapeutics (ALDX) Total Liabilities (2013 - 2026) Analysis & Trends
Aldeyra Therapeutics (ALDX) has 14 years of Total Liabilities data on file, last reported at $24.3 million in Q1 2026.
- Quarterly Total Liabilities fell 17.81% year-over-year to $24.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24.3 million (down 17.81% YoY) and the FY2025 annual result came in at $27.8 million, down 17.24% from the prior year.
- Total Liabilities fell to $24.3 million in Q1 2026, from $27.8 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $33.6 million in Q4 2024 to a low of $24.3 million in Q3 2023.
- A 5-year average of $28.7 million and a median of $28.5 million in 2023 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2022 — Total Liabilities jumped 50.74% — and 2026, when it retreated 17.81%.
- Tracing ALDX's Total Liabilities over 5 years: stood at $30.3 million in 2022, then declined by 5.78% to $28.5 million in 2023, then increased by 17.77% to $33.6 million in 2024, then decreased by 17.24% to $27.8 million in 2025, then decreased by 12.52% to $24.3 million in 2026.
- The last three Total Liabilities figures came in at $24.3 million (Q1 2026), $27.8 million (Q4 2025), and $28.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | Aldeyra Therapeutics | 91.08 Mn | 91.08 Mn | - | 9.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.66 Mn |
| Mar 31, 2026 | 24.33 Mn |
| Dec 31, 2025 | 27.81 Mn |
| Sep 30, 2025 | 28.56 Mn |
| Jun 30, 2025 | 29.67 Mn |
| Mar 31, 2025 | 29.60 Mn |
| Dec 31, 2024 | 33.60 Mn |
| Sep 30, 2024 | 32.22 Mn |
| Jun 30, 2024 | 27.73 Mn |
| Mar 31, 2024 | 27.88 Mn |
| Dec 31, 2023 | 28.53 Mn |
| Sep 30, 2023 | 24.27 Mn |
| Jun 30, 2023 | 25.73 Mn |
| Mar 31, 2023 | 30.98 Mn |
| Dec 31, 2022 | 30.28 Mn |
| Sep 30, 2022 | 27.50 Mn |
| Jun 30, 2022 | 26.99 Mn |
| Mar 31, 2022 | 32.00 Mn |
| Dec 31, 2021 | 27.40 Mn |
| Sep 30, 2021 | 27.55 Mn |